logo
  

Manulife Financial Q2 Profit Declines - Quick Facts

Canada's Manulife Financial Corp. (MFC.TO,MFC) reported Thursday that its second-quarter net income attributed to shareholders declined to C$600 million or C$0.29 per share from last year's C$943 million or C$0.49 per share.

Core earnings, which excluded certain items, was C$902 million or C$0.44 per share, compared to C$701 million or C$0.36 per share a year ago. On average, 6 analysts polled by Thomson Reuters expected earnings of C$0.44 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue was C$1.12 billion, compared to C$13.23 billion in the comparable quarter last year.

Separately, the company approved a quarterly shareholders' dividend of $0.17 per share on the common shares of Manulife Financial Corporation, payable on and after September 21, 2015 to shareholders of record at the close of business on August 18, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT